Oral Treatment with Live Lactobacillus Reuteri Attenuates the Allergic Airway Response in Mice

Forsythe, Paul; Wattie, Jennifer; Inman, Mark D.; Bienenstock, John

doi:10.1016/j.jaci.2005.12.1245

Cited by 90 publications

(127 citation statements)

References 0 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…sensitization with OVA was followed by intranasal OVA challenge. 139,140 Note that one of these studies used a design resembling that of human primary prevention trials in that the probiotic supplementation was started at birth and continued throughout sensitization and challenge. 140 In these studies, oral administration of L. reuteri ATCC 23272, 139 LGG, or Bifi dobacterium animalis ssp.…”

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

“…139,140 Note that one of these studies used a design resembling that of human primary prevention trials in that the probiotic supplementation was started at birth and continued throughout sensitization and challenge. 140 In these studies, oral administration of L. reuteri ATCC 23272, 139 LGG, or Bifi dobacterium animalis ssp. lactis Bb-12 140 signifi cantly decreased airway hyperresponsiveness and the infl ux of eosinophils and macrophages in bronchoalveolar lavage fl uid obtained 24 h after intranasal challenge.…”

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

“…Instead, upregulation of systemic, though not pulmonary, activity of IDO was observed after oral administration of L. reuteri ATCC 23272. 139 IDO is an important immune control enzyme and mediator of peripheral tolerance, and its stimulation suggests the induction of regulatory mechanisms. Such a mechanism was shown more directly to be involved in the dampening of airway hyperreactivity after oral administration of LGG or B. animalis ssp.…”

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Probiotics and immunity

et al. 2009

View full text Add to dashboard Cite

Probiotics are defi ned as live microorganisms that, when administered in adequate amounts, confer a health benefi t on the host, including the gastrointestinal tract. While this benefi cial effect was originally thought to stem from improvements in the intestinal microbial balance, there is now substantial evidence that probiotics can also provide benefi ts by modulating immune functions. In animal models, probiotic supplementation is able to provide protection from spontaneous and chemically induced colitis by downregulating infl ammatory cytokines or inducing regulatory mechanisms in a strain-specifi c manner. In animal models of allergen sensitization and murine models of asthma and allergic rhinitis, orally administered probiotics can straindependently decrease allergen-specifi c IgE production, in part by modulating systemic cytokine production. Certain probiotics have been shown to decrease airway hyperresponsiveness and infl ammation by inducing regulatory mechanisms. Promising results have been obtained with probiotics in the treatment of human infl ammatory diseases of the intestine and in the prevention and treatment of atopic eczema in neonates and infants. However, the fi ndings are too variable to allow fi rm conclusions as to the effectiveness of specifi c probiotics in these conditions.

show abstract

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Probiotics and immunity

et al. 2009

View full text Add to dashboard Cite

show abstract

“…78 Certain probiotics (LGG or Bifidobacterium lactis and Lactobacillus reuteri) have been shown to decrease airway hyper-responsiveness and inflammation by inducing regulatory mechanisms. 81,82 However, definitive conclusions are lacking because of the variety of experimental protocols used. Before using probiotics for asthma prevention, further studies using molecular methods to test for microbiota 83 and large-scale analyses are required.…”

Section: Probioticsmentioning

confidence: 99%

“…; 71 Chitosan/i.n. 77 Phase I/IIa study on chitin microparticles for allergic rhinitis subjects (ClinicalTrials.gov, identifier: NCT00443495) Probiotics Lactobacillus spp., Bifidobacterium spp./oral 81,82 Clinical trial results are still diverse for each study/oral 87…”

Section: Probioticsmentioning

confidence: 99%

Strategies of mucosal immunotherapy for allergic diseases

Chuang

Chiang

2011

Cell Mol Immunol

View full text Add to dashboard Cite

Incidences of allergic disease have recently increased worldwide. Allergen-specific immunotherapy (SIT) has long been a controversial treatment for allergic diseases. Although beneficial effects on clinically relevant outcomes have been demonstrated in clinical trials by subcutaneous immunotherapy (SCIT), there remains a risk of severe and sometimes fatal anaphylaxis. Mucosal immunotherapy is one advantageous choice because of its non-injection routes of administration and lower side-effect profile. This study reviews recent progress in mucosal immunotherapy for allergic diseases. Administration routes, antigen quality and quantity, and adjuvants used are major considerations in this field. Also, direct uses of unique probiotics, or specific cytokines, have been discussed. Furthermore, some researchers have reported new therapeutic ideas that combine two or more strategies. The most important strategy for development of mucosal therapies for allergic diseases is the improvement of antigen formulation, which includes continuous searching for efficient adjuvants, collecting more information about dominant T-cell epitopes of allergens, and having the proper combination of each. In clinics, when compared to other mucosal routes, sublingual immunotherapy (SLIT) is a preferred choice for therapeutic administration, although local and systemic side effects have been reported. Additionally, not every allergen has the same beneficial effect. Further studies are needed to determine the benefits of mucosal immunotherapy for different allergic diseases after comparison of the different administration routes in children and adults. Data collected from large, well-designed, double-blind, placebo-controlled, and randomized trials, with post-treatment follow-up, can provide robust substantiation of current evidence.

show abstract

The influence of the young microbiome on inflammatory diseases—Lessons from animal studies

Bendtsen

Fisker

Hansen

et al. 2015

Birth Defects Research Pt C

View full text Add to dashboard Cite

Chronic inflammatory diseases are on the rise in the Westernized world. This rise has been correlated to a range of environmental factors, such as birth mode, rural versus urban living conditions, and use of antibiotics. Such environmental factors also influence early life gut microbiota (GM) colonization and maturation--and there is growing evidence that the negative effects of these factors on human health are mediated via GM alterations. Colonization of the gut initiates priming of the immune system from birth, driving tolerance towards non-harmful microorganisms and dietary antigens and proper reactions towards invading pathogens. This early colonization is crucial for the establishment of a healthy GM, and throughout life the balanced interaction of GM and immune system is a key element in maintaining health. An immune system out of balance increases the risk for later life inflammatory diseases. Animal models are indispensable in the studies of GM influence on disease mechanisms and progression, and focus points include studies of GM modification during pregnancy and perinatal life. Here, we present an overview of animal studies which have contributed to our understanding of GM functions in early life and how alterations affect risk and expression of certain inflammatory diseases with juvenile onset, including interventions, such as birth mode, antibiotics, and probiotics.

show abstract

Oral Treatment with Live Lactobacillus Reuteri Attenuates the Allergic Airway Response in Mice

Cited by 90 publications

References 0 publications

Probiotics and immunity

Probiotics and immunity

Strategies of mucosal immunotherapy for allergic diseases

The influence of the young microbiome on inflammatory diseases—Lessons from animal studies

Contact Info

Product

Resources

About